![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:4391N Celsis International PLC 6 July 2000 AGM STATEMENT The following is an extract from a statement made by Dr. Chris Evans, Chairman of Celsis, at today's Annual General Meeting. "In the report and accounts for the year ended 31st March 2000 we reported a second full year of significant profits increase, with no exceptional costs. These very positive results establish the Company as a market leader and leave the Group well placed to exploit many expansion opportunities in its chosen markets. "Following the restructuring and reorganisation of the Group in 1998/1999 the Company is now lead by Sales and Marketing personnel. A clearly focused strategy is being pursued, to increase the Company's presence in both new and existing markets and to capitalise upon our leading products and proprietary technology. The Company's research and development activities are also more closely driven by customer demand and market feedback. "End Screening continues to provide good revenue growth and offers areas of significant expansion opportunity for the Company. We will focus on our Global Corporate Account Management roll out programmes; increasing our presence in the pharmaceutical industry; and strengthening our leadership position in existing markets, particularly personal care and dairy products, through product improvements. "Celsis Laboratory Group (CLG) is taking advantage of the increasing trend to outsource testing, from new and current customers. CLG now provides its customers with faster quality services at lower costs following the facilities upgrade. "The Company will continue to drive forward and direct its own sales in hygiene monitoring. Focus on systemSURE and product upgrades in this area will strengthen our position in hygiene monitoring." Enquiries Celsis International plc Jack Rowell, Chief Executive +44-1223-426008 Brunswick James Garthwaite +44-207-404-5959 Notes to Editors Celsis International plc Celsis International plc specialises in the development and supply of rapid diagnostic and monitoring systems to detect and measure microbial contamination. It has successfully developed tests for use in the food, beverage, pharmaceutical, cosmetic and toiletries industries. These tests are based upon the technology of ATP Bioluminescence; such tests detect the presence of microbial contamination by monitoring light emitted when adenosine triphosphate ("ATP"), a naturally occurring substance present in all living organisms, is brought into contact with luciferase, an enzyme produced by fireflies.
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions